⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3158869 | 0.67 | — | — | |
| SCHEMBL318754 | 0.67 | — | — | |
| SCHEMBL14401791 | 0.67 | — | — | |
| SCHEMBL988025 | 0.67 | — | — | |
| Hydrochloric Acid SCHEMBL21855056 | 0.62 | — | — | |
| SCHEMBL1038139 | 0.59 | — | — | |
| SCHEMBL11683648 | 0.59 | — | — | |
| SCHEMBL11239430 | 0.56 | — | — | |
| SCHEMBL290742 | 0.56 | — | — | |
| Hydrochloric Acid SCHEMBL21855077 | 0.56 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1585511-B1 | ASTHMA AND ALLERGIC INFLAMMATION MODULATORS | AMGEN INC (US) | 2013-01-23 | — | — | EP | disclosed |
| US-20130012506-A1 | ANTI-INFECTIVE PYRIDO (1,2-A) PYRIMIDINES | NO ZAESUNG (KR) | 2013-01-10 | — | — | US | disclosed |
| WO-2013001830-A1 | NUCLEOSIDE ANTIBIOTIC DERIVATIVE | 国立大学法人北海道大学 (JP) | 2013-01-03 | — | — | WO | disclosed |
| US-20070112200-A1 | Non-racemic hexafluoreleucine,and methods of making and using it | TRUSTEES OF TUFTS COLLEGE (US) | 2007-05-17 | — | — | US | disclosed |
| US-20070072862-A1 | Bis-aryl amide compounds and methods of use | AMGEN INC. | 2007-03-29 | — | — | US | disclosed |
| WO-2007015757-A2 | INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR-A MODULATORS; SYNTHESES OF SUCH MODULATORS AND METHODS OF USING SUCH MODULATORS | NEREUS PHARMACEUTICALS, INC. (US) | 2007-02-08 | — | — | WO | disclosed |